BACKGROUND: Cryptococcal meningitis and tuberculosis are both important causes of death in persons with advanced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Cytomegalovirus (CMV) viremia may be associated with increased mortality in persons living with HIV who have tuberculosis. It is unknown whether concurrent CMV viremia is associated with mortality in other AIDS-related opportunistic infections.
METHODS: We prospectively enrolled Ugandans living with HIV who had cryptococcal meningitis from 2010-2012. Subsequently, we analyzed stored baseline plasma samples from 111 subjects for CMV DNA. We compared 10-week survival rates among those with and without CMV viremia.
RESULTS: Of 111 participants, 52% (58/111) had detectable CMV DNA (median plasma viral load 498 IU/mL, interquartile range [IQR] 259-2390). All samples tested were positive on immunoglobin G serology. The median CD4+ T cell count was 19 cells/µL (IQR 9-70) and did not differ by the presence of CMV viremia (P = .47). The 10-week mortality rates were 40% (23/58) in those with CMV viremia and 21% (11/53) in those without CMV viremia (hazard ratio 2.19, 95% confidence interval [CI] 1.07-4.49; P = .03), which remained significant after a multivariate adjustment for known risk factors of mortality (adjusted hazard ratio 3.25, 95% CI 1.49-7.10; P = .003). Serum and cerebrospinal fluid cytokine levels were generally similar and cryptococcal antigen-specific immune stimulation responses did not differ between groups.
CONCLUSIONS: Half of persons with advanced AIDS and cryptococcal meningitis had detectable CMV viremia. CMV viremia was associated with an over 2-fold higher mortality rate. It remains unclear whether CMV viremia in severely immunocompromised persons with cryptococcal meningitis contributes directly to this mortality or may reflect an underlying immune dysfunction (ie, cause vs effect).
CLINICAL TRIALS REGISTRATION: NCT01075152.
Bibliographical noteFunding Information:
Potential conflicts of interest. G. M. has received grants from the Wellcome Trust and South African Government. M. R. S. has received consulting fees from Sanofi Vaccines and GSK Vaccines, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (grant numbers T32AI055433, U01AI089244, and K23AI138851); the Eunice Kennedy Shriver National Institute of Child Health and Human Development [grant number R01HD079918]); the National Institute of Neurologic Disorders and Stroke (grant number R01NS086312); the Fogarty International Center (grant numbers K01TW010268 and K43TW010718); and a combined National Institute of Neurologic Disorders and Stroke and Fogarty International Center award (grant number D43TW009345) via the Northern Pacific Global Health Fellows Program.
© The Author(s) 2019.
- Cryptococcal meningitis